Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: A randomized case-controlled study

References

• Mughal T. Anaemia in patients with cancer: An overview. In: Bokemeyer C, Ludwig H, editors. ESO scientific updates, anaemia in cancer., vol. 6 Amsterdam: Elsevier Science BV; 2001. p 15–23.
   Google Scholar
• Vogelzang N, Breitbart W, Cella D. Patient, cargeiver, and oncolgist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol 1997;34\(Suppl. 2): 4–12.
   Google Scholar
• Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001;91:2214–2221.
   PubMed Web of Science ®Google Scholar
• Nowrousian M. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapyinduced anaemia in patients with solid tumours. Med Oncol 1998;15\(Suppl. 1): S19—S28.
   PubMedGoogle Scholar
• Koeller J. Clinical guidelines for the treatment of cancer-realted anemia. Pharmacotherapy 1998;18:156–169.
   PubMed Web of Science ®Google Scholar
• Mercadente S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000;26:303–311.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Chin Oncol 2001;19:2875–2882.
   PubMed Web of Science ®Google Scholar
• Varan A, Bilyiikpamukçu M, Kutluk T, Akyfiz C. Recombi-nant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 1999;103:E16—E19.
   Web of Science ®Google Scholar
• Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172–179.
   Google Scholar
• Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, doubleblind, placebo-controlled trial. J Pediatr 1996;129:656–660.
   Google Scholar
• Bennetts G, Bertolone S, Bray G, et al. Erythropoietin reduces volume of red cell transfusions required in some subsets of children with acute lymphocytic leukemia. Blood (Abstract) 1995;10:853a.
   Google Scholar
• Kronberger M, Fischmeister G, Potschger U, et al. Early prophylactic treatment with high-dose recombinant human erythropoietin (rHu-EPO) in children with solid tumors. Med Pediatr Oncol (Abstract) 1999;33:285.
   Google Scholar
• Bolonaki I, Stiakaki E, Lydaki E, Dimitriou H, Kambourakis A, Kalmantis T, Kalmanti M. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996;13:111–121.
   PubMed Web of Science ®Google Scholar
• Ragni G, Clerico A, Sordi A, et al. Recombinant human erythropoietin (rHuEPO) in children with cancer: A random-ized study. Med Pediatr Oncol (Abstract) 1998;31:274.
   Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Chin Oncol 1998;16:3412–3425.
   Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15: 1218–1234.
   Google Scholar
• Littlewood T, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double blind, placebo-controlled trial. J Chin Oncol 2001;19:2865–2874.
   Google Scholar
• Seidenfeld J, Piper M, Flamm C. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 193:1204–1214.
   Google Scholar
• American Society of Clinical Oncology. American Society of Hematology Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303–2320.
   Google Scholar
• European Organisation for Research and Treatment of Cancer (EORTC) Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P. Taskforce for the Elderly. EORTTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40:2201–2216.
   PubMed Web of Science ®Google Scholar
• Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992;19(Suppl 8):29–35.
   PubMedGoogle Scholar
• Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Chin North Am 1994;8:961–973.
   PubMed Web of Science ®Google Scholar
• Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombi-nant human erythropoietin. Cancer 1994;73:2535–2542.
   PubMed Web of Science ®Google Scholar
• Beck MN, Beck D. Recombinant erythropoietin in acute chemotherapy induced anemia of children with cancer. Med Ped Oncol 1995;25:17–21.
   PubMedGoogle Scholar
• Tamary H, Danon YL. Recombinant human erythropoietin in children with cancer. Pediatr Hematol Oncol 1996;13: 305–308.
   PubMed Web of Science ®Google Scholar
• Leon P, Jimenez M, Barona P, Sierrasesumaga L. Recombi-nant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998;30:110–116.
   PubMedGoogle Scholar
• Yilmaz D, Çetingül N, Öniz H, Kansoy S, Kavakli K. A Single institutional experience: Is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 2004;21:1–8.
   PubMed Web of Science ®Google Scholar
• de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Chin Oncol 1995;13:1623–1631.
   PubMed Web of Science ®Google Scholar
• Kronberger M, Fischmeister G, Poetschger U, Gadner H, Zoubek A. Reduction in transfusion requirement with early epoetin alfa treatment in pediatric patients with solid tumors: A case-control study. Pediatr Hematol Oncol 2002;19: 95–105.
   Google Scholar
• Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528–1536.
   Google Scholar
• Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888–895.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Chin Oncol 2004; 22:1301–1307.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aphasia and epoetin therapy. N Engl J Med 2004;351: 1403–1408.
   PubMed Web of Science ®Google Scholar
• Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red-cell aphasia: A retrospective study. Lancet 2004;363: 1768–1771.
   PubMed Web of Science ®Google Scholar
• Braun MM, Wise RP, Wood JJ. Epoetin and pure red-cell aphasia. N Engl J Med 2005;352:511–512.
   PubMedGoogle Scholar
• Razzouk BI, Hord JD, Hockenbarry M, Hinds PS, Feusner J, Williams D, Rackoff WR. Double-blind, placebo-controlled study of quality of life, hematologic and points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Chin Oncol 2006;24: 3583–3589.
   Google Scholar